K
Kim Govaerts
Publications - 5
Citations - 167
Kim Govaerts is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 98 citations.
Papers
More filters
Journal ArticleDOI
Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment.
Kim Govaerts,Robin J. Lurvink,I.H.J.T. de Hingh,K. Van der Speeten,Laurent Villeneuve,S. Kusamura,Vahan Kepenekian,M. Deraco,O. Glehen,B. J. Moran,Pedro Barrios-Sanchez,Joel M. Baumgartner,Almog Ben-Yaacov,Rosella Bertulli,Peter H Cashin,Tom Cecil,Sanjeev Dayal,Michele De Simone,Jason M. Foster,Diane Goéré,Kuno Lehmann,Yan Li,Brian W. Loggie,Faheez Mohamed,David L. Morris,Aviram Nissan,Pompiliu Piso,Marc Pocard,Beate Rau,Marc A. Reymond,Lucas Sideris,John Spiliotis,Paul H. Sugarbaker,Victor J. Verwaal,Malcom S. Wilson,Yutaka Yonemura,Yang Yu +36 more
TL;DR: Recommendations are provided based on three Delphi voting rounds with GRADE-based questions amongst a panel of 80 worldwide PMP experts based on an overview and analysis of the literature on mucinous appendiceal tumours with, or without, PMP.
Journal ArticleDOI
A bronchogenic cyst, presenting as a retroperitoneal cystic mass
TL;DR: The surgical excision of a retroperitoneal bronchogenic cyst that presented as a non-functioning left adrenal mass is reported, highlighting the rarity of this pathologic entity.
Journal ArticleDOI
Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients.
TL;DR: There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients, and the pharmacologic base underlying these treatment regimens is clarified.
Book ChapterDOI
The Basis of Regional Therapy, Pharmacology, Hyperthermia, and Drug Resistance
TL;DR: How the tumor microenvironment plays a crucial role and the effects of hyperthermia is discussed, the molecular basis of drug effectiveness/resistance at the gene as well as the protein level is understood, and why high concentrations of the therapeutic agent at the level of the tumor do not necessarily translate into greater efficacy are explained.